XML 54 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Segment Information (Tables)
 9 Months Ended
Mar. 31, 2024
Segment Reporting [Abstract]  
Disaggregation of Revenue [Table Text Block]
The following tables present revenue for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
Three Months Ended March 31,
(in millions)20242023
Pharmaceutical and Specialty Solutions$50,651 $46,496 
Global Medical Products and Distribution3,113 2,989 
Nuclear and Precision Health Solutions352 313 
at-Home Solutions
743 651 
OptiFreight® Logistics
72 61 
Other
1,167 1,025 
Total segment revenue54,931 50,510 
Corporate (1)
(20)(23)
Total revenue$54,911 $50,487 
Nine Months Ended March 31,
(in millions)20242023
Pharmaceutical and Specialty Solutions$154,524 $139,441 
Global Medical Products and Distribution9,264 9,140 
Nuclear and Precision Health Solutions1,006 875 
at-Home Solutions
2,188 1,986 
OptiFreight® Logistics
198 177 
Other
3,392 3,038 
Total segment revenue167,180 151,619 
Corporate (1)
(61)(60)
Total revenue$167,119 $151,559 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Revenue from External Customers by Geographic Areas [Table Text Block]
The following tables present revenue by geographic area:
Three Months Ended March 31,
(in millions)20242023
United States$53,715 $49,343 
International1,216 1,167 
 Total segment revenue54,931 50,510 
Corporate (1)(20)(23)
Total revenue$54,911 $50,487 
Nine Months Ended March 31,
(in millions)20242023
United States$163,548 $148,186 
International3,632 3,433 
Total segment revenue167,180 151,619 
Corporate (1)(61)(60)
Total revenue$167,119 $151,559 
(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.
Segment Profit by Reportable Segment
The following tables present segment profit for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
Three Months Ended March 31,
(in millions)20242023
Pharmaceutical and Specialty Solutions
$580 $560 
Global Medical Products and Distribution
20 (46)
Other (1)111 106 
Total segment profit711 620 
Corporate(344)(48)
Total operating earnings
$367 $572 
Nine Months Ended March 31,
(in millions)20242023
Pharmaceutical and Specialty Solutions
$1,541 $1,394 
Global Medical Products and Distribution
18 (175)
Other (1)319 305 
Total segment profit1,878 1,524 
Corporate(1,043)(934)
Total operating earnings
$835 $590 
(1)Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics.
Assets by Reportable Segment
The following table presents total assets for the two reportable segments and the remaining operating segments, included in Other, and Corporate:
(in millions)March 31,
2024		June 30,
2023
Pharmaceutical and Specialty Solutions
$30,496 $27,615 
Global Medical Products and Distribution
7,357 7,961 
Other (1)2,692 2,621 
Corporate 5,335 5,220 
Total assets$45,880 $43,417 
(1)Comprised of the remaining operating segments, Nuclear and Precision Health Solutions, at-Home Solutions and OptiFreight® Logistics.